Metabotype analysis for personalized biology: a new bioanalytical territory for high-resolution MS
References
- 1 Psychogios N, Hau DD, Peng J et al. The human serum metabolome. PLoS One6,e16957 (2011).
- 2 Joyner MJ, Pedersen BK. Ten questions about systems biology. J. Physiol.589,1017–30 (2011).
- 3 Henry H, Sobhi HR, Scheibner O, Bromirski M, Nimkar SB, Rochat B. Comparison between a high-resolution single-stage Orbitrap and a triple quadrupole mass spectrometer for quantitative analyses of drugs. Rapid Commun. Mass Spectrom.26,499–509 (2012).
- 4 Ramanathan R, Korfmacher W. The emergence of high-resolution MS as the premier analytical tool in the pharmaceutical bioanalysis arena. Bioanalysis4,467–469 (2012).
- 5 Rochat B, Kottelat E, McMullen J. The future key role of LC–high-resolution-MS analyses in clinical laboratories: a focus on quantification. Bioanalysis4,2939–2958 (2012).
- 6 Dunn WB, Broadhurst D, Begley P et al. Human serum metabolome (HUSERMET) consortium. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc.6,1060–1083 (2011).
- 7 Yuan M, Breitkopf SB, Yang X, Asara JM. A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat. Protoc.7,872–881 (2012).
- 8 Vuckovic D. Current trends and challenges in sample preparation for global metabolomics using liquid chromatography–mass spectrometry. Anal. Bioanal. Chem.403,1523–1548 (2012).
- 9 Gika HG, Theodoridis GA, Vrhovsek U, Mattivi F. Quantitative profiling of polar primary metabolites using hydrophilic interaction ultrahigh performance liquid chromatography–tandem mass spectrometry. J. Chromatogr. A1259,121–127 (2012).
- 10 Dumlao DS, Buczynski MW, Norris PC, Harkewicz R, Dennis EA. High-throughput lipidomic analysis of fatty acid derived eicosanoids and N-acylethanolamines. Biochim. Biophys. Acta.1811,724–736 (2011).
- 11 Nicholls AW. Realising the potential of metabolomics. Bioanalysis4,2195–2197 (2012).
- 12 Dunn WB, Broadhurst D, Brown M et al. Metabolic profiling of serum using ultra performance liquid chromatography and the LTQ-Orbitrap mass spectrometry system. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.871,288–98 (2008).
- Nicholson G, Rantalainen M, Maher AD et al. Human metabolic profiles are stably controlled by genetic and environmental variation. Mol. Syst. Biol.7,525 (2011).
- 14 Plebani M, Lippi G. Personalized (laboratory) medicine: a bridge to the future. Clin. Chem. Lab. Med.6,1–4 (2013).
- 15 Sottas PE, Kapke GF, Vesterqvist O, Leroux JM. Patient-specific measures of a biomarker for the generation of individual reference intervals: hemoglobin as example. Transl. Res.158,360–368 (2011).
- 16 Sottas PE, Vernec A. Current implementation and future of the Athlete Biological Passport. Bioanalysis4,1645–1652 (2012).
- 17 Sottas PE, Kapke GF, Leroux JM. Adaptive bayesian approach to clinical trial renal impairment biomarker signal from urea and creatinine. Int. J. Biol. Sci.9,156–163 (2013).
- 18 Adamski J, Suhre K. Metabolomics platforms for genome wide association studies-linking the genome to the metabolome. Curr. Opin. Biotechnol.24,39–47 (2013).
- 19 Suhre K, Shin SY, Petersen AK et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature477,54–60 (2011).
- 20 Bellcross CA, Page PZ, Meaney-Delman D. Direct-to-consumer personal genome testing and cancer risk prediction. Cancer J.18,293–302 (2012).